



MIT Course 15.S21 (formerly 15.975) Nuts and Bolts of New Ventures/Business Plans

Richard Kivel

Rich Kivel has devoted his career to investing in business ventures and serving on boards that have changed the course of life sciences and technology in the global market.

His passion has been focused on the expansion of entrepreneurial ecosystems globally and the advancement of innovation. Rich served as Chairman of the Global MIT Enterprise Forum and brought new life to the 35 year old organization—expanding into Russia, Turkey, Singapore, London, Spain, South Korea, and Iceland.

Currently Rich is a guest lecturer at many universities in Europe, Russia and the US including Skolkovo and MIT and serves as a Trustee of the Bankinter Foundation of Innovation, a global Innovation Think-Tank based in Madrid, Spain.

Professionally:

As CEO of MolecularWare (an MIT spin-out), he built a team that pioneered complex data visualization and bioinformatics for researchers around the world. The company was acquired.

As CEO of TheraGenetics (London based), he assembled a world-class science team to develop first-ever pharmacogenetic tests for personalized CNS diagnostics and successfully sold the company.

As Founder of Chairman of Rhapsody Biologics (Singapore based) the firm has created a versatile Personalized Peptide Vaccine (PPV) platform to predict and optimize peptide vaccines for use at an individual and population level. The company is still in operation.

Rich is currently working with high-growth companies and global investors at various stages of development such as ViS Research, CounterPoint Health Solutions, G3.eu and others.

Previously, Rich was recruited by Bridgewater Associates, the world's largest hedge fund with \$150B in global investments.

